Quietum Plus

The label — what’s actually in the Quietum Plus capsule

Quietum Plus is a capsule supplement sold primarily through ClickBank, positioned squarely at the tinnitus and hearing-health market. Its sales funnel’s hook is that tinnitus is caused by damaged neural pathways between the ear and the brain, and that the blend “nourishes” these pathways back to health.

Before reviewing the ingredients, it is worth stating the mechanism problem plainly: no oral supplement has a published randomized controlled trial demonstrating efficacy for tinnitus in humans. The cochlea, auditory nerve, and central auditory processing pathway are not accessible to botanicals in the way the funnel implies. The ingredients below can be fairly evaluated on their own merits — but their merits have nothing to do with hearing.

Per the Supplement Facts panel from a unit purchased April 2026:

Ingredient	Dose disclosed	What it’s doing on the label
Proprietary blend	undisclosed total	—
└ Mucuna pruriens (standardized for L-DOPA)	undisclosed	”Nourishes neural wires”
└ Maca root (Lepidium meyenii)	undisclosed	Energy and vitality framing
└ Epimedium (Herba Epimedii)	undisclosed	Circulation framing
└ Dong quai (Angelica sinensis)	undisclosed	Blood flow to auditory nerve framing
└ Oat straw (Avena sativa green tops)	undisclosed	Brain nourishment framing
└ L-tyrosine	undisclosed	Neurotransmitter precursor framing

Not a single ingredient on this label has been tested in a human tinnitus trial at any dose.

Ingredient-by-ingredient evidence review

Mucuna pruriens

The strongest ingredient on the label, by general evidence quality — and entirely irrelevant to tinnitus. Mucuna pruriens seed extract is the richest botanical source of L-DOPA outside pharmaceutical preparation, with roughly 4–7% L-DOPA by weight in standardized extracts. A 2004 RCT by Katzenschlager et al. (Neurology 63:936–943) found 15 g of raw mucuna powder (delivering ~340 mg L-DOPA) produced comparable Parkinson’s motor improvement to standard carbidopa-levodopa therapy, with fewer dyskinesias.

This is an auditory supplement’s version of putting aspirin in a hair-growth formula because aspirin reduces inflammation and inflammation is bad. The pathway from “dopamine precursor” to “tinnitus relief” has not been walked in any published human trial at any dose.

Maca root (Lepidium meyenii)

Maca’s clinical evidence base is almost entirely in the domains of libido, menopausal symptoms, and male fertility. A 2010 systematic review by Shin et al. (BMC Complement Altern Med 10:44) identified 4 RCTs, all small, all showing modest positive effects on sexual function and well-being at 1.5–3 g/day. Zero auditory trials.

Epimedium (Herba Epimedii)

Icariin, the primary active flavonoid in epimedium, inhibits PDE5 similarly to sildenafil — hence its classification as a “natural Viagra” in traditional Chinese medicine. A 2016 review (Pan et al., Molecules 21:1481) documents extensive preclinical research on bone density, cardiovascular function, and neuroprotection in rodents. Human trials are limited and do not include any auditory endpoint.

Dong quai (Angelica sinensis)

Dong quai is a phytoestrogenic botanical with a 2,000-year history in traditional Chinese medicine for “women’s conditions.” Its main active compounds — z-ligustilide and ferulic acid — have antispasmodic and anti-inflammatory properties in rodent models (Zhong et al., 2011, J Ethnopharmacol). No human tinnitus data exists. Its phytoestrogenic load is a clinically relevant safety consideration.

Oat straw (Avena sativa green tops)

Oat straw extract is marketed for cognitive performance and cerebrovascular blood flow. A 2015 double-blind crossover study (Kennedy et al., Nutrients 7:3089) found a single 1600 mg dose of oat straw extract improved attention task performance in healthy adults. The dose studied is 1,600 mg; the dose Quietum Plus can plausibly contain is in the tens of milligrams. There is no auditory endpoint in any oat straw trial.

L-tyrosine

L-tyrosine is the amino acid precursor to dopamine, norepinephrine, and thyroid hormones. At doses of 100–150 mg/kg, it has evidence for maintaining cognitive performance under acute stress (Lieberman et al., 1995, Brain Res Bull 36:189–193). This dose in a typical adult is 7,000–10,500 mg — many times more than a capsule supplement can deliver. The stress-cognitive literature also has nothing to do with auditory physiology.

The ginkgo problem — and why it matters here

Quietum Plus does not contain ginkgo biloba. It does not need to, to understand the bar it must clear. Ginkgo is the only herbal ingredient that has ever had a plausible biological case and a serious clinical trial record for tinnitus: it promotes cochlear microcirculation, modulates platelet activating factor, and has antioxidant effects in auditory tissue in animal models. Despite that mechanism story, the 2013 Cochrane systematic review by Hilton MP, Zimmermann EF, and Hunt WT (Cochrane Database Syst Rev 2013, Issue 3, CD003852) examined four RCTs totaling 1,543 participants and found: “There is no reliable evidence that ginkgo biloba is effective for tinnitus.” If ginkgo — with 30 years of tinnitus research — cannot move the needle, an aphrodisiac-and-mood formula assembled from botanicals with zero tinnitus trials has no credible claim at all.

The math: cost per clinical dose

Quietum Plus asks $49–69 per month for an undisclosed dose of each ingredient. Let’s compare what the same ingredients cost at their only studied doses — for the conditions they have actually been studied in:

Ingredient	Clinical dose (studied condition)	Monthly cost, commodity
Mucuna pruriens (15 g raw / ~450 mg L-DOPA for Parkinson’s support)	N/A — not achievable in capsule form	—
Maca root 1,500–3,000 mg (libido/menopausal)	NOW Maca 750 mg, 100 caps	$7.00 (at 60–120 caps)
L-tyrosine 500 mg (stress cognition)	Jarrow L-Tyrosine 500 mg, 100 caps	$6.50 (at 30 caps)
Oat straw 1,600 mg (acute cognitive)	Bulk Supplements oat straw extract	~$8.00
Total for what these ingredients actually do	—	~$22/month

None of those commodity doses treat tinnitus. Neither does Quietum Plus. The difference is that the commodity buyer is not paying $49–69 for a tinnitus claim that has never been tested.

Marketing teardown

The Quietum Plus funnel reviewed April 18, 2026, opens with a narrator describing tinnitus as a condition caused by “deteriorated neural wires” and claims the ingredients in the formula “repair and regenerate” those connections. This is a fabricated mechanism with no anatomical basis — cochlear nerve fibers do not regenerate in response to oral botanical supplementation, and no study has measured any neural regeneration endpoint for any ingredient in this blend.

The funnel includes:

• A claimed endorsement from an unnamed “ENT specialist” whose credentials are not verifiable. No institution is cited. No license number is provided.
• Before-and-after testimonials from individuals whose identities are not verifiable. Two of the testimonial photos reverse-image-searched to generic stock photography sources.
• Claims that the formula was “developed based on research from leading universities.” No university, researcher, or paper is named.
• A countdown timer that resets on page reload — the same client-side setTimeout architecture documented in our Puravive and Mitolyn reviews.
• Pre-purchase upsell to a “Quietum Plus Liver Detox” product that has no plausible connection to auditory health, indicating the tinnitus angle is a funnel entry point rather than a product mission.

The population targeted by Quietum Plus — people with chronic tinnitus, many of whom have already tried conventional medicine without resolution — is one of the most vulnerable to this kind of marketing. Tinnitus is distressing, poorly treated by existing pharmacotherapy, and effectively incurable for most sufferers. A supplement funnel exploiting that gap deserves a correspondingly direct assessment: this product cannot deliver what the funnel promises, and the funnel knows it.

What we’d want to see before revising this verdict

• Any published RCT of any ingredient in this blend for any auditory endpoint in humans
• Disclosed individual ingredient doses to allow even a theoretical dose-adequacy assessment
• A named, verifiable clinician associated with the formulation who can defend the mechanism claim
• Removal of the “neural wire regeneration” framing, which is scientifically indefensible

None of these exist as of April 2026. The bar to “Conditional” here is not just transparency — it is the existence of tinnitus evidence for at least one ingredient at the dose delivered. That evidence does not exist for anything in the formula.

Bottom line

Quietum Plus sells hope to people with a genuinely miserable neurological symptom, using a mechanism claim that no published science supports and an ingredient list assembled for a different category entirely. The Cochrane review found that even ginkgo biloba — the most studied herbal candidate for tinnitus — does nothing. The Quietum Plus formulation doesn’t even include ginkgo. It includes libido and mood botanicals rebranded as auditory nutrients.

Skeptic Desk verdict: Avoid — 2.5/10. The 60-day ClickBank guarantee is the only consumer protection worth noting. Spend the $49–69 on a single visit to an audiologist, who may identify a treatable underlying cause.